WilmerHale Counsels Cynosure in $1.65B Acquisition by Hologic

Download IconDownload Print IconPrint

WilmerHale Counsels Cynosure in $1.65B Acquisition by Hologic

Firm News

Related Solutions

Lawyers with deep and broad experience counseling clients in every industry on the design, implementation, and interpretation of executive compensation arrangements and on general compensation and benefits issues.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.

Cynosure (Nasdaq: CYNO), a developer and manufacturer of aesthetic treatment systems, and Hologic (Nasdaq: HOLX), a developer, manufacturer and supplier of diagnostics, medical imaging and surgical products, today announced the sale of Cynosure to Hologic in a transaction worth approximately $1.65 billion. The transaction is expected to close during late March or April of 2017.

The WilmerHale team on the transaction was led by Hal Leibowitz and Jason Kropp and included Andrew Bonnes, Kim Wethly, Leon Greenfield, Bruce Manheim, Steve Barrett, Laura Schneider, Amy Null, Julie Hogan Rodgers, Ciara Baker, Davis Sluis, Caroline Dotolo, Leah Segal and Alex Civetta. 

Read the press release for more information. 

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel